On Apr. 20, 2020, Novartis announced it had reached an agreement with the U.S. Food and Drug Administration (FDA) to proceed with a Phase III clinical trial with approximately 440 patients to evaluate the use of hydroxychloroquine for the treatment of hospitalized patients with COVID-19 disease.

The clinical trial drug supply were provided by Sandoz, the generics and biosimilars division of Novartis.